Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study
NS Gooneratne, P Gehrman… - Journal of Clinical …, 2010 - jcsm.aasm.org
Study Objectives: To evaluate the effectiveness of ramelteon, a melatonin receptor agonist,
for the treatment of insomnia in older adults starting auto-titrating positive airway pressure …
for the treatment of insomnia in older adults starting auto-titrating positive airway pressure …
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea
Ramelteon is a selective MT 1/MT 2-receptor agonist indicated for insomnia treatment.
Because it has no depressant effects on the nervous system, it is not expected to affect the …
Because it has no depressant effects on the nervous system, it is not expected to affect the …
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia
T Roth, D Seiden, S Sainati, S Wang-Weigand, J Zhang… - Sleep medicine, 2006 - Elsevier
BACKGROUND AND PURPOSE: To assess the efficacy and safety of ramelteon, a selective
MT1/MT2 receptor agonist, for chronic insomnia treatment. PATIENTS AND METHODS …
MT1/MT2 receptor agonist, for chronic insomnia treatment. PATIENTS AND METHODS …
A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia
T Roth, D Seiden, S Wang-Weigand… - … medical research and …, 2007 - Taylor & Francis
Objective: To assess the efficacy and safety of ramelteon, a selective melatonin MT1/MT2-
receptor agonist, for insomnia treatment in older adults. Methods: In a randomized, 9‑week …
receptor agonist, for insomnia treatment in older adults. Methods: In a randomized, 9‑week …
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as …
L Mini, S Wang-Weigand, J Zhang - Clinical therapeutics, 2008 - Elsevier
Background: Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
US Food and Drug Administration for insomnia treatment. Objective: The aim of this post hoc …
An efficacy, safety, and dose–response study of ramelteon in patients with chronic primary insomnia
M Erman, D Seiden, G Zammit, S Sainati, J Zhang - Sleep medicine, 2006 - Elsevier
BACKGROUND AND PURPOSE: To evaluate the efficacy, safety, and dose response of
Ramelteon, a novel highly selective MT1/MT2 receptor agonist, in patients with chronic …
Ramelteon, a novel highly selective MT1/MT2 receptor agonist, in patients with chronic …
Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis
A Kuriyama, M Honda, Y Hayashino - Sleep medicine, 2014 - Elsevier
Ramelteon is the first selective melatonin receptor agonist and currently is approved in the
United States and Japan for the treatment of insomnia. Our meta-analysis assessed the …
United States and Japan for the treatment of insomnia. Our meta-analysis assessed the …
Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis
S Wang-Weigand, M McCue, F Ogrinc… - … medical research and …, 2009 - Taylor & Francis
Objective: Ramelteon is an MT1/MT2 melatonin receptor agonist indicated for the treatment
of insomnia characterized by difficulty with sleep onset. In previous clinical studies …
of insomnia characterized by difficulty with sleep onset. In previous clinical studies …
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia
G Zammit, M Erman, S Wang-Weigand… - Journal of Clinical …, 2007 - jcsm.aasm.org
Objective: To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor agonist) in
subjects with chronic primary insomnia. Methods: Randomized, multicenter, double-blind …
subjects with chronic primary insomnia. Methods: Randomized, multicenter, double-blind …
Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia
S Wang-Weigand, M Watissée, T Roth - Sleep medicine, 2011 - Elsevier
OBJECTIVE: Ramelteon is an MT1/MT2 melatonin receptor agonist approved in the US and
Japan for the treatment of sleep-onset insomnia. This study evaluated the effects of …
Japan for the treatment of sleep-onset insomnia. This study evaluated the effects of …